Company intelligence / Profile preview

3D Medicines Inc.

Qingdao, Shandong, Chinaen.3d-medicines.com ↗

Ownership: Public · 1244.HK
Employees: ~191
Development stage: Commercial

Overview

The company’s lead product Envafolimab—a subcutaneous anti-PD-L1 antibody—has been commercialized for MSI-H/dMMR advanced solid tumors. The pipeline includes late-stage assets such as peptide vaccines and novel receptor antagonists targeting various solid tumors. Several programs are in pivotal or registration trials across multiple oncology indications.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Small moleculesPeptide cancer vaccines
Industry: Biotech

Drug pipeline

14 assets

envafolimab

13 more assets in the full pipeline.

Request access →

Partnerships

Commercialization through external production/sales partnerships mentioned but specific partners not listed by name.License-in assets also referenced but no partner names provided.

Beyond the preview

Go deeper on 3D Medicines Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D Medicines Inc..

Explore the full profile